logo
Sign In
  1. Home
  2. Search
FiltersReset Filters
6 results

  • ambien

    (zolpidem tartrate)
    Medication Details
    sanofi-aventis U.S. LLC
    Usage: AMBIEN (zolpidem tartrate) is indicated for the short-term treatment of insomnia, specifically for difficulties with sleep initiation. It effectively reduces sleep latency for up to 35 days, as demonstrated in controlled clinical studies lasting 4–5 weeks.
    Medication Details
    Drug Interactions

  • ambien

    (zolpidem tartrate)
    Medication Details
    sanofi-aventis U.S. LLC
    Usage: AMBIEN CR (zolpidem tartrate extended-release tablets) is indicated for the short-term treatment of insomnia, particularly for difficulties with sleep onset and/or maintenance, as measured by wake time after sleep onset. Clinical trials supporting its efficacy lasted up to 24 weeks.
    Medication Details
    Drug Interactions

  • ferrlecit

    (sodium ferric gluconate complex)
    Medication Details
    sanofi-aventis U.S. LLC
    Usage: Ferrlecit is indicated for treating iron deficiency anemia in adults and pediatric patients aged 6 and older with chronic kidney disease on hemodialysis and receiving supplemental epoetin therapy.
    Medication Details
    Drug Interactions

  • ferrlecit

    (sodium ferric gluconate complex)
    Medication Details
    sanofi-aventis U.S. LLC
    Usage: Ferrlecit is indicated for treating iron deficiency anemia in adults and pediatric patients aged 6 and older with chronic kidney disease undergoing hemodialysis and receiving supplemental epoetin therapy.
    Medication Details
    Drug Interactions

  • mozobil

    (PLERIXAFOR)
    Medication Details
    sanofi-aventis U.S. LLC
    Usage: Mozobil is indicated, in combination with filgrastim, for mobilizing hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma or multiple myeloma.
    Medication Details
    Drug Interactions

  • zaltrap

    (ziv-aflibercept)
    Medication Details
    sanofi-aventis U.S. LLC
    Usage: ZALTRAP, combined with fluorouracil, leucovorin, and irinotecan (FOLFIRI), is indicated for patients with metastatic colorectal cancer (mCRC) that is resistant to or has progressed after treatment with an oxaliplatin-containing regimen.
    Medication Details
    Drug Interactions
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
For ProvidersRequest DemoJoin Research Panel
Prescribing toolsPrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutCareersContact UsSecurity
Get the latest insights in your inbox
  • Terms and Conditions
  • Privacy Policy
  • © 2026 PrescriberPoint. All Rights Reserved.